Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of ibrutinib when given together
with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur
or spread (higher risk) and who were previously treated or untreated and unfit for or refused
intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth.